[Clinical study of a low-dose contraceptive--Femodene].Akush Ginekol (Sofiia). 1995; 34(3):71-3.AG
The authors present their clinical experience with a low-dose monophasic contraceptive consisting of 30 mcg ethinylestradiol and 75 mcg a gestagen--gestodene (Femoden, Schering). 112 menstrual cycles of 22 women in fertile age were followed. The results show 100% contraception, a good control of the menstrual cycle and tolerance of the preparation.